SCHEDULE 13G/A: Deep Track Capital Maintains Passive Stake in 4D Molecular Therapeutics, Reports 1.32% Ownership

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed an amended Schedule 13G disclosing a continued passive beneficial ownership of 1.32% in 4D Molecular Therapeutics Inc.'s common stock as of December 31, 2024.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin jointly filed an Amendment No. 5 to Schedule 13G.
• The filing reports beneficial ownership of 609,900 shares of Common Stock, par value $0.0001 per share, of 4D Molecular Therapeutics Inc.
• This ownership represents 1.32% of the issuer's class of securities.
• The calculation of the percentage is based on 46,227,709 Common Stock outstanding as of November 12, 2024, as reported in the issuer's 10-Q filed on November 13, 2024.
• The reporting persons collectively hold shared voting power and shared dispositive power over all 609,900 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory filing.

Positives

• The filing indicates continued investment by an institutional investor, Deep Track Capital, in 4D Molecular Therapeutics, suggesting ongoing confidence in the company's long-term prospects from this investor's perspective.

Risks

• The filing itself does not detail specific risks related to 4D Molecular Therapeutics Inc.'s operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.

Management Comments

• David Kroin, Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and Director for Deep Track Biotechnology Master Fund, Ltd., certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

4D Molecular Therapeutics Inc. operates in the biotechnology sector, focusing on gene therapy. Deep Track Capital is an investment firm with a specialization in biotechnology. This filing reflects a passive investment by a sector-focused fund in a biotech company, which is a common occurrence in the industry as institutional investors take positions in promising companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership structure and the passive stake held by a significant institutional investor group.
• Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership.

Key Dates

Keywords

4D Molecular Therapeutics, Deep Track Capital, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, Passive Stake, SEC Filing